Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice.

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced today that Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.[1]

GE Healthcare introduced an expansion of the line of Caring Magnetic Resonance (MR) Suites, built by PDC, that now includes designs specific to GE’s Extremity Optima 430s MR scanner.

Molecular breast imaging company Gamma Medica, Inc. is expanding the capabilities of its LumaGEM Molecular Breast Imaging (MBI) System with a biopsy accessory. Gamma Medica’s technology clearly lights up tumors, even those obscured by dense breast tissue. This new LumaGUIDE hardware and software package, currently a work-in-progress, will allow physicians to precisely identify and biopsy suspicious lesions. The new procedure is quick (about half the time of an MRI-guided biopsy), easy-to-use, and streamlined.

Advanced Radiation Therapy (ART), manufacturer of the AccuBoost System for radiation therapy of partial breast and Elekta a global leader in cancer management systems and software, announced today that they have executed an agreement whereby ART acquires the assets of all AccuBoost installations held by Elekta, its worldwide distribution partner. As part of the transaction, ART has purchased the assets and the operating agreements for more than 20 installations in the U.S. The transaction is designed to enable both companies to focus on their core competencies, and serves AccuBoost user groups by allowing ART to increase its support to these installations.